{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:39:44Z","timestamp":1791725984874,"version":"4.3.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2018CDF-2372"],"award-info":[{"award-number":["TMA2018CDF-2372"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2018SF-2476"],"award-info":[{"award-number":["TMA2018SF-2476"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A case of multidrug-resistant tuberculosis is presented. It highlights the role of whole-genome sequencing, expanded phenotypic drug susceptibility testing, and enhanced case management, offering a more complete understanding of drug susceptibility to Mycobacterium tuberculosis. This approach guides an effective individualized treatment strategy that results in rapid sustained culture conversion.<\/jats:p>","DOI":"10.1093\/cid\/ciaa526","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T12:10:57Z","timestamp":1588594257000},"page":"2981-2985","source":"Crossref","is-referenced-by-count":7,"title":["Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing"],"prefix":"10.1093","volume":"71","author":[{"given":"Navisha","family":"Dookie","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa"},{"name":"South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesri","family":"Padayatchi","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa"},{"name":"South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Lessells","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa"},{"name":"KwaZulu-Natal Research Innovation and Sequencing, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherise L","family":"Naicker","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa"},{"name":"South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunitha","family":"Chotoo","sequence":"additional","affiliation":[{"name":"King Dinu-Zulu Hospital Complex, South African National Department of Health, eThekwini Health District, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa"},{"name":"South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"2021010207401615200_CIT0001","volume-title":"Consolidated guidelines on drug-resistant tuberculosis treatment 2019","author":"World Health Organization","year":"2019"},{"key":"2021010207401615200_CIT0002","volume-title":"Global Tuberculosis report 2019","author":"World Health Organization","year":"2019"},{"key":"2021010207401615200_CIT0003","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkx506","article-title":"Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care","volume":"73","author":"Dookie","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021010207401615200_CIT0004","author":"Stop TB Partnership"},{"key":"2021010207401615200_CIT0005","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMc1815121","article-title":"Bedaquiline microheteroresistance after cessation of tuberculosis treatment","volume":"380","author":"de Vos","year":"2019","journal-title":"N Engl J Med"},{"key":"2021010207401615200_CIT0006","author":"Center for the AIDS Programme of Research in South Africa"},{"key":"2021010207401615200_CIT0007","volume-title":"Management of rifampicin-resistant tuberculosis: a clinical reference guide","author":"South African National Department of Health","year":"2019"},{"key":"2021010207401615200_CIT0008","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021010207401615200_CIT0009","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","article-title":"Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations","volume":"8","author":"Lempens","year":"2018","journal-title":"Sci Rep"},{"key":"2021010207401615200_CIT0010","doi-asserted-by":"crossref","first-page":"e00092","DOI":"10.1128\/AAC.00092-19","article-title":"Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping MIC distributions with different underlying resistance mechanisms","volume":"63","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2021010207401615200_CIT0011","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021010207401615200_CIT0012","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2021010207401615200_CIT0013","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5588\/ijtld.19.0414","article-title":"Molecular-based tuberculosis drug susceptibility testing: one size fits all?","volume":"23","author":"Chesov","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021010207401615200_CIT0014","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/cid\/cix486","article-title":"Of testing and treatment: implications of implementing new regimens for multidrug-resistant tuberculosis","volume":"65","author":"Dowdy","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa526\/33517025\/ciaa526.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/11\/2981\/35349406\/ciaa526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/11\/2981\/35349406\/ciaa526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T12:40:36Z","timestamp":1609591236000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/11\/2981\/5834727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,5,8]]},"published-print":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa526","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,5,8]]}}}